Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Clinical Trial to Confirm the Safety of TREAKISYM Liquid Formulation (Rapid Infusion Injection Formulation)

Next Previous
Trial Profile

Phase III Clinical Trial to Confirm the Safety of TREAKISYM Liquid Formulation (Rapid Infusion Injection Formulation)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Registrational
  • Sponsors SymBio Pharmaceuticals

    • Most Recent Events

    • 10 May 2021 According to a Eagle Pharmaceuticals media release, the company has filed TREAKISYM RI (50ml) liquid formulation with the Pharmaceuticals and Medical Devices Agency ("PMDA") in Japan, based on data from this study.
    • 09 Sep 2020 According to a SymBio Pharmaceuticals media release, the company submitted a New Drug Application for marketing authorization of TREAKISYM ready to dilute liquid formulation in September 2019.
    • 09 Sep 2020 According to a SymBio Pharmaceuticals media release, the company has completed the observation period for all patients (last patient last visit)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top